Aktienanalyse zu Pulse Biosciences Inc (PLSE)PLSEPulse Biosciences Inc

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Currently, Pulse Biosciences Inc is not an ideal buy due to its high volatility and negative financial performance. The current price is $44.43, with a recent RSI of 26.016 indicating oversold conditions. However, the company has a forward P/E of 0 and a gross margin of 37.10% in Q2 2026, suggesting potential for future profitability. The main risk is the significant net loss of $24,657,000 in Q2 2026, which raises concerns about sustainability.